Bionoid Pharma Statistics
Total Valuation
Bionoid Pharma has a market cap or net worth of 5.94 million.
| Market Cap | 5.94M |
| Enterprise Value | n/a |
Important Dates
| Earnings Date | n/a |
| Ex-Dividend Date | n/a |
Share Statistics
Bionoid Pharma has 53.99 million shares outstanding.
| Current Share Class | 53.99M |
| Shares Outstanding | 53.99M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +29.41% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | n/a |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 64.38 |
| PB Ratio | -5.19 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.07
| Current Ratio | 0.07 |
| Quick Ratio | 0.03 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -5.64 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -164.12% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | 34.93% |
| Revenue Per Employee | 18,452 |
| Profits Per Employee | -324,589 |
| Employee Count | 5 |
| Asset Turnover | 0.62 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -56.00% in the last 52 weeks. The beta is -4.33, so Bionoid Pharma's price volatility has been lower than the market average.
| Beta (5Y) | -4.33 |
| 52-Week Price Change | -56.00% |
| 50-Day Moving Average | 0.08 |
| 200-Day Moving Average | 0.19 |
| Relative Strength Index (RSI) | 52.90 |
| Average Volume (20 Days) | 33,401 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.00 |
Income Statement
In the last 12 months, Bionoid Pharma had revenue of 92,258 and -1.62 million in losses. Loss per share was -46.27.
| Revenue | 92,258 |
| Gross Profit | 47,484 |
| Operating Income | -389,018 |
| Pretax Income | -1.62M |
| Net Income | -1.62M |
| EBITDA | -385,710 |
| EBIT | -389,018 |
| Loss Per Share | -46.27 |
Balance Sheet
The company has 27,916 in cash and 454,698 in debt, giving a net cash position of -426,782 or -0.01 per share.
| Cash & Cash Equivalents | 27,916 |
| Total Debt | 454,698 |
| Net Cash | -426,782 |
| Net Cash Per Share | -0.01 |
| Equity (Book Value) | -1.14M |
| Book Value Per Share | -29.92 |
| Working Capital | -1.16M |
Cash Flow
| Operating Cash Flow | -357,621 |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | 51.47% |
| Operating Margin | -421.66% |
| Pretax Margin | -1,757.00% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Bionoid Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -171.32% |
| Shareholder Yield | n/a |
| Earnings Yield | -27.33% |
| FCF Yield | n/a |
Stock Splits
The last stock split was on February 25, 2020. It was a reverse split with a ratio of 0.0004.
| Last Split Date | Feb 25, 2020 |
| Split Type | Reverse |
| Split Ratio | 0.0004 |
Scores
Bionoid Pharma has an Altman Z-Score of -221.7. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -221.7 |
| Piotroski F-Score | n/a |